(Q53545682)

15 May 2018

title

Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer. (English)

1 reference

15 May 2018

main subject

phase I clinical trial

0 references

0 references

6

1 reference

15 May 2018

William Pao

8

object named as

William Pao

1 reference

15 May 2018

Daniel T Milton

1

1 reference

15 May 2018

Gregory J Riely

2

1 reference

15 May 2018

Christopher G Azzoli

3

1 reference

15 May 2018

Jorge E Gomez

4

1 reference

15 May 2018

Robert T Heelan

5

1 reference

15 May 2018

Lee M Krug

7

1 reference

15 May 2018

Barbara Pizzo

9

1 reference

15 May 2018

Naiyer A Rizvi

10

1 reference

15 May 2018

Vincent A Miller

11

1 reference

15 May 2018

language of work or name

English

0 references

publication date

1 August 2007

1 reference

15 May 2018

published in

Cancer

1 reference

15 May 2018

volume

110

1 reference

15 May 2018

page(s)

599-605

1 reference

15 May 2018

issue

3

1 reference

15 May 2018

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22816

7 January 2021

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22816

7 January 2021

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22816

7 January 2021

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22816

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22816

7 January 2021

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22816

7 January 2021

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22816

7 January 2021

Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22816

7 January 2021

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22816

7 January 2021

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22816

7 January 2021

Erlotinib in lung cancer - molecular and clinical predictors of outcome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22816

7 January 2021

Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22816

7 January 2021

Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22816

7 January 2021

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22816

7 January 2021

Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22816

7 January 2021

High frequency of mutations of the PIK3CA gene in human cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22816

7 January 2021

Non-small cell lung cancers frequently express phosphorylated Akt; an immunohistochemical study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22816

7 January 2021

Signaling pathways in NSCLC as a predictor of outcome and response to therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22816

7 January 2021

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22816

7 January 2021

Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22816

7 January 2021

Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22816

7 January 2021

Clinical experience with everolimus (Certican) in young renal transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22816

7 January 2021

Practical management of patients with non-small-cell lung cancer treated with gefitinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22816

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22816

7 January 2021

Identifiers

DOI

10.1002/CNCR.22816

1 reference

15 May 2018

PubMed ID

17577220

1 reference

15 May 2018